Patents Assigned to Nanjing IASO Biotherapeutics Co., Ltd.
  • FULLY HUMANIZED BISPECIFIC CHIMERIC ANTIGEN RECEPTOR TARGETING CD19 AND CD22 AND USE THEREOF
    Publication number: 20230241212
    Abstract: Provided is a bispecific chimeric antigen receptor targeting CD19 and CD22, which comprises extracellular antigen binding domains of heavy-chain variable regions and light-chain variable regions of anti-CD19 and anti-CD22 antibodies. Further provided is a bispecific CAR-T cell targeting CD19 and CD22.
    Type: Application
    Filed: June 30, 2021
    Publication date: August 3, 2023
    Applicant: Nanjing IASO Biotherapeutics Co., Ltd.
    Inventors: Yongkun Yang, Guang Hu, Taochao Tan, Zhenyu Dai, Panpan Niu, Guangrong Meng, Wei Cheng, Xiangyin Jia, Jialu Mo, Wen Wang, Bailu Xie, Junfeng Yang, Fei Zhou
  • FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF
    Publication number: 20230174654
    Abstract: The present invention provides an anti-CD22 antibody molecule and a CD22-targeted chimeric antigen receptor (CAR) constructed using the anti-CD22 antibody molecule. The present invention also provides an application of the anti-CD22 antibody molecule and the CAR in the preparation of drugs for treating CD22-related diseases.
    Type: Application
    Filed: April 2, 2021
    Publication date: June 8, 2023
    Applicant: Nanjing IASO Biotherapeutics Co., Ltd.
    Inventors: Guang Hu, Yongkun Yang, Panpan Niu, Guangrong Meng, Wei Cheng, Jialu Mo
  • FULLY HUMAN ANTIBODY TARGETING CD19 AND APPLICATION THEREOF
    Publication number: 20220220200
    Abstract: Provided are a fully human antibody targeting CD19 or a single chain antibody or fragment thereof. Further provided is a chimeric antigen receptor (CAR) constructed by using a single chain antibody (scFv) derived from the fully human antibody. The fully human antibody and the CAR can be used for the construction of CAR-T cells targeting CD19. Compared with CAR-T cells using murine antibodies, the CAR-T cells have better compatibility with the human body, which is beneficial to their long-term proliferation and survival in the body.
    Type: Application
    Filed: May 20, 2020
    Publication date: July 14, 2022
    Applicant: NANJING IASO BIOTHERAPEUTICS CO., LTD.
    Inventors: Taochao Tan, Zhenyu Dai, Xiangyin Jia, Qiaoe Wei, Yongkun Yang
  • Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
    Patent number: 11266690
    Abstract: The invention provides a chimeric antigen receptor (CAR) which can specifically bind to a BCMA protein comprising a BCMA binding structural domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain. The invention also provides uses of the CAR in treating diseases or conditions linked to the expression of BCMA.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: March 8, 2022
    Assignees: Nanjing IASO Biotherapeutics Co., Ltd., Innovent Biologics (Suzhou) Co., Ltd.
    Inventors: Jianfeng Zhou, Junjian Liu, Guang Hu, Yongkun Yang, Guangrong Meng, Wenjing Gao, Yuyu Wang, Panpan Niu
  • Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
    Patent number: 11026975
    Abstract: The invention provides a chimeric antigen receptor (CAR) which can specifically bind to a BCMA protein comprising a BCMA binding structural domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The invention also provides uses of the CAR in treating diseases or conditions linked to the expression of BCMA.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 8, 2021
    Assignees: Nanjing IASO Biotherapeutics Co., Ltd., Innovent Biologics (Suzhou) Co., Ltd.
    Inventors: Jianfeng Zhou, Junjian Liu, Guang Hu, Yongkun Yang, Guangrong Meng, Wenjing Gao, Yuyu Wang, Panpan Niu